Keywords Congenital diaphragmatic hernia - Prenatal diagnostics - Fetal magnetic resonance
imaging
Introduction
Congenital diaphragmatic hernia (CDH) is a major birth defect accounting for 8% of
all congenital anomalies [1 ]. Upon defective diaphragm development, abdominal viscera within the thoracic cavity
impair lung and heart development. As a result of respiratory failure due to lung
hypoplasia and severe pulmonary hypertension which may result in heart failure, CDH-affected
children face life-threatening cardiopulmonary conditions. Nevertheless, the survival
of CDH-affected neonates has greatly improved, particularly if treated in specialized
centers. Evidently, one of the main reasons for this is advances in postnatal care
(e.g., improved ventilation strategies, extracorporeal membrane oxygenation [ECMO],
and surgery). On the other hand, refined prenatal diagnostic imaging helps to establish
an optimized environment for postnatal care. Due to the intrathoracic hernia, congenital
diaphragm defects are usually determined reliably by prenatal ultrasound. Here, lower
lung-to-head ratio (LHR) values and liver herniation were identified as predictors
of the survival of CDH-affected neonates more than two decades ago [2 ]. Several years later, the observed-to-expected LHR (o/e-LHR) was measured to consider
the inaccuracy of the LHR, since it depends on the gestational age. Henceforth, despite
the lack of standardized prognostic parameters, the ultrasound-evaluated o/e-LHR persisted
as the most validated predictor of morbidity and mortality in CDH [3 ]
[4 ]
[5 ]. It is noteworthy that there are different ways to assess the o/e-LHR value or lung
volume: first, longest diameter; second, anteroposterior diameter; and third, tracing
method [6 ]. With advances in fetal magnetic resonance imaging (MRI), this diagnostic imaging
method holds great potential for more accurate measurements of the fetal lung and
thus a more accurate prognosis. Consequently, MRI-evaluated fetal lung volume was
suggested as an outcome predictor for CDH [7 ] and was hypothesized to correlate with the probability of chronic lung disease (CLD)
[8 ]. Fetal MRI has therefore been implemented in standard prenatal care protocols at
many centers. However, since prenatal risk assessment remains a pivotal issue, current
scientific efforts try to identify the prognostic parameter best associated with morbidity
and mortality. We therefore aimed to correlate the well-established ultrasound o/e-LHR
representing the standard of prenatal diagnostic imaging with MRI-evaluated o/e-LHR
values (the longest diameter method and tracing method) and relative fetal lung volume
(rFLV) to investigate the possibilities and limitations of prenatal MRI imaging for
the prediction CDH morbidity and mortality.
Materials and methods
Study cohort and design
We conducted a retrospective cohort study to compare prenatal imaging techniques for
CDH. All newborns with CDH treated at our center between 01/2013 and 12/2021 who underwent
prenatal MRI examination within 7 days after sonography were eligible. The exclusion
criteria were syndromes, genetic alterations, and major additional congenital anomalies.
Furthermore, all patients with MRI examinations before 28 and after 34 weeks of gestation
were excluded for reasons of physiological lung growth and image quality. Incomplete
datasets were also excluded from the study. Fetuses who underwent fetoscopic endoluminal
tracheal occlusion (FETO) were ruled out. For details on the screening process, refer
to [Fig. 1 ]. Concerning prenatal imaging, ultrasound-o/e-LHR, MRI-evaluated o/e-LHR, and relative
fetal lung volume (rFLV) were evaluated and compared as the primary outcome. As secondary
outcome parameters, the need for ECMO, the incidence and severity of chronic lung
disease (CLD), and the survival to discharge were analyzed. The study was conducted
in accordance with the Declaration of Helsinki and approved by the local ethics committee.
Fig. 1 Flowchart representing the composition of the study population. * One patient was
diagnosed with tetralogy of Fallot and also exhibited a copy number variation. He
therefore fulfilled both exclusion criteria and was listed twice.
Imaging Techniques
Sonography was performed on high-quality instruments (Voluson 750 Expert, Voluson
E8 or E10, GE Healthcare ultrasound Systems, Germany). Each examination was carried
out by one of three experienced ultrasound specialists. The o/e-LHR was determined
using the freely available calculator according to perinatology (https://perinatology.com/calculators/LHR.htm).
The fetal head circumference was measured on an axial plane image of the fetal head
at the level of the paired thalami and third ventricle.
MRI-based evaluation of o/e-LHR was performed according to both the Longest Diameter
and the Tracing method (example given in [Fig. 2 ]). Additionally, the relative fetal lung volume (rFLV) measured by MRI was considered
a significant prognostic marker and the same cut-off values as for the o/e-LHR were
evaluated. Fetal MRI was performed using a 1.5 Tesla MRI system (Magnetom Sonata or
Avanto, Siemens Healthineers) without fetal sedation. Head circumference, o/e-LHR,
and rFLV were measured by manual plotting using commercially available volume analysis
software (Argus, Leonardo Workstation, version VB19A-SP1, Siemens Healthcare and Aycan
OsiriX) in transverse planes with T2-weighted HASTE sequences applied using a 4 mm
slice thickness. For each diagnostic modality, o/e-LHR values were calculated as published
previously [9 ]. Considering the rFLV, lung tissue on both sides was included in the measurement
only sparing the hilar region. rFLV was calculated as published previously [10 ]. Analysts measuring the lung sonographically or via MRI were blinded for clinical
outcome.
Fig. 2 MRI-assisted methods for o/e-LHR measurement (A–E ) and ultrasound evaluation of o/e-LHR according to the longest diameter and area
method (F ). First, the fetal head circumference was evaluated (A ). Then, o/e-LHR was assessed by both the MRI-Tracing Method (B ) and the MRI-Longest Diameter Method (C ) as described. The MRI-based relative fetal lung volume (D–E ) was measured as described. The displayed MRI and ultrasound data were obtained from
different individuals.
ECMO initiation and diagnosis of CLD
ECMO was performed if criteria according to recommendations by the CDH EURO consortium
were met [11 ]. At our center, the preferred ECMO mode was veno-arterial as reported by Rafat et
al. [12 ]. CLD was diagnosed if there was an additional need for oxygen supplementation on
day 28 after birth, as reported before [13 ].
Data Analysis
Categorical variables are presented as percentages. Continuous variables are presented
as mean ± standard deviation (SD). Statistical calculations were performed using SAS
software, release 9.4 (SAS Institute Inc., Cary, NC, USA). The mean values of two
groups were compared by two-sample t-tests (in the case of normally distributed data)
or the Mann-Whitney U-test. To compare groups regarding qualitative parameters, Chi-square
or Fisher’s exact test were used, where appropriate. Kappa coefficients, the McNemar
test, and Bowker’s test were used to assess the degree of agreement. Cohen’s Kappa
was interpreted according to Kwiecien et al. [14 ]. Prediction of survival, CLD, and ECMO was performed using the SAS PROC LOGISTIC
procedure for the different diagnostic methods. The area under the ROC curve (AUC)
was assessed to quantify the predictive ability of the model. A p-value of < 0.05
was considered statistically significant.
Results
Demographic and clinical characteristics of the study cohort
A total of 293 fetuses with CDH underwent prenatal sonography and prenatal MRI examination
within the following 7 days. 203 fetuses met the inclusion criteria. For an overview
of the recruitment and the characteristics of the dropouts, please see [Fig. 1 ]. 177 neonates exhibited left-sided (LCDH) and 26 had right-sided (RCDH) diaphragm
defects. ECMO was initiated in 96 cases of which 77 exhibited liver herniation and
19 did not (p<0.0001). Overall survival to discharge was 76.8% and did not differ
significantly between LCDH and RCDH (76.3% vs. 80.8%, p=0.6446). For a detailed overview
of the study population, please refer to [Table 1 ].
Table 1 Characterization of the study population.
LCDH, n=177
RCDH, n=26
p -value
LCDH = left-sided congenital diaphragmatic hernia, RCDH = right-sided congenital diaphragmatic
hernia, PHT = pulmonary hypertension, NO = nitric oxide. p -values were calculated only where appropriate.
Birth weight [g]
2964±542
3106±502
ns
Liver-up, n (%)
102 (57.6)
26 (100)
< 0.0001
Liver-down, n (%)
75 (42.4)
0 (0.00)
< 0.0001
Severe PHT, n (%)
124 (70.1)
25 (96.2)
< 0.01
Duration of NO in survivals [d]
16.2±11.7
19.6±7.33
ns
Patch closure, n (%)
136 (76.8)
21 (80.8)
ns
Boston Scale, n (%)
7 (3.95)
1 (3.85)
–
49 (27.7)
2 (7.69)
–
58 (32.8)
14 (53.8)
–
17 (9.60)
3 (11.5)
–
Kitano score, n (%)
19 (10.7)
26 (100)
–
55 (31.1)
0 (0.00)
–
66 (37.3)
0 (0.00)
–
37 (20.9)
0 (0.00)
–
Survival, n (%)
135 (76.3)
21 (80.8)
Ns
Comparison of imaging techniques
Each fetus was allocated to one of four groups based on o/e-LHR or rFLV values (<15%,
15–25%, 25–35%, >35%) for every diagnostic method individually ([Table 2 ]). LCDH and RCDH are presented separately. With sonography, no o/e-LHR value <15%
was determined. However, using MRI, o/e-LHR values <15% could indeed be detected.
These individuals had low survival rates ranging from 0% to 50.0% – depending on the
diagnostic method. For every diagnostic method, however, the incidences of ECMO and
CLD decreased, and survival increased gradually, thus reaching a minimum and maximum,
respectively, for o/e-LHR and rFLV values >35%.
Table 2 Different methods to measure o/e-LHR. Comparison of ultrasound and MRI (lung area
vs. longest diameter).
Ultrasound
MRI Tracing
MRI Longest Diameter
MRI rFLV
For overall cases of ECMO, CLD, and survival per group, the denominator is the total
number of study participants for each group. When divided by LCDH and RCDH, the denominator
is the total count of cases of LCDH and RCDH per group.
CDH = congenital diaphragmatic hernia, o/e-LHR = observed-to-expected lung-to-head
ratio, MRI = magnetic resonance imaging, ECMO = extracorporeal membrane oxygenation,
CLD = chronic lung disease, rFLV = relative fetal lung volume, RCDH = right-sided
CDH, LCDH = left-sided CDH. * p<0.05, ∆ p<0.05, ∆∆ p<0.05.
o/e-LHR < 15%, n=0
o/e-LHR < 15%, n=1
o/e-LHR < 15%, n=2
rFLV < 15%, n=3
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
Overall, n (%)
0 (0.00)
0 (0.00)
0 (0.00)
1 (50.0)
0 (0.00)
1 (50.0)
3 (100)
1 (33.3)
1 (33.3)
LCDH
1 (100)
0 (0.00)
0 (0.00)
0 (0.00)
2 (100)
1 (50.0)
0 (0.00)
1 (50.0)
2 (66.6)
2 (100)
0 (0.00)
0 (0.00)
RCDH
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
1 (33.3)
1 (100)
1 (100)
1 (100)
o/e-LHR 15–25%, n=21
o/e-LHR 15–25%, n=2
MRI o/e-LHR 15–25%, n=22
rFLV 15–25%, n=50
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
Overall, n (%)
15 (71.4)
14 (66.7)
10 (47.6)
2 (100)
1 (50.0)
1 (50.0)
16 (72.7)
13 (59.1)
12 (54.5)
35 (70.0)
31 (62.0)
33 (66.0)
LCDH
17 (81.0)
11 (64.7)
10 (58.8)
7 (41.6)
2 (100)
2 (100)
1 (50.0)
1 (50.0)
21 (95.5)
15 (71.4)
12 (57.1)
11 (52.4)
40 (80.0)
26 (65.0)
22 (55.0)
25 (62.5)
RCDH
4 (19.0)
4 (100)
4 (100)
3 (75.0)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
1 (4.55)
1 (100)
1 (100)
1 (100)
10 (20.0)
9 (90.0)
9 (90.0)
8 (80.0)
o/e-LHR 25–35%, n=58
o/e-LHR 25–35%, n=39
MRI o/e-LHR 25–35%, n=48
rFLV 25–35%, n=77
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
Overall, n (%)
35 (60.3)
30 (51.7)
36 (62.1)
26 (66.7)
24 (61.5)
25 (64.1)
27 (56.3)
29 (60.4)
32 (66.7)
42 (54.5)
45 (58.4)
53 (68.8)
LCDH
54 (93.1)
33 (61.1)
29 (53.7)
35 (64.8)
38 (97.4)
25 (65.8)
23 (60.5)
24 (63.2)
48 (100)
27 (56.3)
29 (60.4)
32 (66.7)
64 (83.1)
34 (53.1)
37 (57.8)
44 (68.8)
RCDH
4 (6.90)
2 (50.0)
1 (25.0)
1 (25.0)
1 (2.56)
1 (100)
1 (100)
1 (100)
0 (0.00)
0 (0.00)
0 (0.00)
0 (0.00)
13 (16.9)
8 (61.5)
8 (61.5)
9 (69.2)
o/e-LHR > 35%, n=116
o/e-LHR > 35%, n=161
MRI o/e-LHR > 35%, n=131
rFLV > 35%, n=70
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
ECMO
CLD
Survival
Overall, n (%)
42 (36.2)
54 (46.6)
102 (87.9)
68 (42.2)*
76 (47.2)∆
131 (83.4)∆∆
49 (37.4)
58 (44.3)
112 (85.5)
15 (21.4)*
22 (31.4)∆
68 (97.1)∆∆
LCDH
99 (85.3)
30 (30.3)
41 (41.4)
86 (86.9)
136 (84.5)
50 (36.8)
59 (43.4)
111 (81.6)
106 (80.9)
31 (29.2)
41 (38.7)
92 (86.8)
68 (97.1)
14 (20.6)
22 (32.4)
66 (97.1)
RCDH
17 (14.7)
12 (70.6)
13 (76.5)
16 (94.1)
25 (15.5)
18 (72.0)
17 (68.0)
20 (80.0)
25 (19.1)
18 (72.0)
17 (68.0)
20 (80.0)
2 (2.86)
1 (50.0)
0 (0.00)
2 (100)
Cohen’s Kappa (K) was evaluated to measure the degree of agreement between each of
the diagnostic methods with regard to the sonographic method as the standard of perinatal
care. Cohen’s Kappa, therefore, allowed conclusion of how reliably one individuum
was allocated to the same o/e-LHR or rFLV group, respectively, throughout different
diagnostic methods. For the MRI longest diameter method compared to sonography, shifts
within the diagnostic cohorts appeared to be insignificant (p=0.5233) and a slight
correlation was found (K=0.2413) for each of the outcome parameters ECMO, CLD, and
survival. Concerning the MRI-based o/e-LHR (Tracing method) or rFLV compared to ultrasound-evaluated
o/e-LHR, correlation remained poor. Details are presented in Supplementary Table 1 . When considering overall comparisons instead of intraindividual consistency, significant
differences could be determined between groups in favor of the MRI-evaluated rFLV
compared to the MRI Tracing method particularly in the o/e-LHR >35% and rFLV >35%,
respectively. Both the incidences of ECMO (21.4% vs. 42.2%, p<0.05) and CLD (31.4%
vs. 47.2%, p<0.05) were diminished, whereas survival to discharge further increased
(97.1% vs. 83.4%, p<0.05) if a fetus exhibited an rFLV >35% compared to a fetus who
had only been evaluated with an o/e-LHR value >35% by MRI Tracing method.
Our ROC analyses indicate that each of the different diagnostic modalities is able
to predict postnatal morbidity and mortality in cases of LCDH ([Table 3 ]). The prediction of survival seems to work out best based on the MRI evaluation
of rFLV (AUC=0.80, p<0.0001). Even for RCDH, CLD could be predicted by o/e-LHR evaluated
by the MRI Longest Diameter method (AUC=0.74, p<0.05) and rFLV (AUC=0.93, p<0.05).
Table 3 Predictive ability of different diagnostic methods.
LCDH
RCDH
Method
Prediction of
AUC
p -value
AUC
p -value
LCDH = left-sided congenital diaphragmatic hernia, RCDH = right-sided congenital diaphragmatic
hernia, o/e-LHR = observed-to-expected lung-to-head ratio, MRI = magnetic resonance
imaging, LD = longest diameter method, rFLV = relative fetal lung volume, AUC = area
under the curve, ns = not significant
Sonography o/e-LHR
Survival
0.74
<0.0001
0.75
ns
CLD
0.74
<0.0001
0.85
ns
ECMO
0.70
<0.0001
0.67
ns
MRI tracing o/e-LHR
Survival
0.71
0.0002
0.56
ns
CLD
0.82
<0.0001
0.82
ns
ECMO
0.72
<0.0001
0.65
ns
MRI LD o/e-LHR
Survival
0.72
0.0002
0.46
ns
CLD
0.78
<0.0001
0.74
<0.05
ECMO
0.71
<0.0001
0.58
ns
MRI rFLV
Survival
0.80
<0.0001
0.64
ns
CLD
0.79
<0.0001
0.93
<0.05
ECMO
0.71
<0.0001
0.77
Ns
Incidences of liver-up
In our study, 57.6% of LCDH cases and 100% of RCDH cases were diagnosed with liver-up
(p<0.0001). For every diagnostic method, incidences of liver-up gradually decreased
with growing o/e-LHR and rFLV values, respectively. Among the groups of highest o/e-LHR
and rFLV, liver-up occurred most frequently in the MRI Tracing method (57.1%) and
was minimal if the rFLV was above 35% (37.1%). Details are presented in [Table 4 ]. Notably, liver-up accounted for 80.2% of all required ECMO interventions as compared
to liver-down (19.8%, p<0.0001; data not shown).
Table 4 Incidences of liver-up among groups divided by method.
o/e-LHR
Sonography
Tracing
LD
rFLV
o/e-LHR = observed-to-expected lung-to-head ratio. LD = longest
diameter method, rFLV = relative fetal lung volume. For ultrasound, area and LD, percentages
refer to the o/e-LHR value. Regarding rFLV, percentages refer to the actual rFLV.
< 15%
–
2 (100)
2 (100)
2 (66.6)
15–25%
18 (85.7)
2 (100)
20 (90.9)
46 (92.0)
25–35%
45 (77.6)
33 (84.6)
38 (79.2)
52 (67.5)
> 35%
56 (48.3)
92 (57.1)
68 (51.9)
26 (37.1)
Discussion
The ultrasound-evaluated o/e-LHR is one of the oldest prognostic parameters for CDH
and since sonography is the standard of prenatal care, the ultrasound-evaluated o/e-LHR
is most commonly used. Meanwhile, both total fetal lung volume and the o/e-LHR evaluated
on MRI were shown to be equally valuable prognostic tools [7 ]
[15 ]. For the o/e-LHR, cut-off values as applied herein are generally accepted to classify
the severity of CDH as suggested before [16 ]. Since such consensus for rFLV is not yet available, we used the same cut-off values
as for the o/e-LHR to investigate its prognostic value. For every imaging technique,
the incidences of ECMO and CLD decreased, whereas the probability of survival increased
gradually, reaching a minimum and maximum respectively for o/e-LHR values and rFLV
>35%. Yet, the outcome parameters significantly improved if rFLV was above 35% compared
to MRI-based measurement of o/e-LHR values >35%. Our study shows that different diagnostic
modalities measuring o/e-LHR either via ultrasound or via two different MRI-based
calculations do not correlate well. Also, the rFLV data seem to be distributed more
equally across the different groups (15–25%, 25–35%, >35%) compared to the other diagnostic
modalities where a shift towards the best prognostic group (o/e-LHR>35%) occurred.
A possible explanation could be the inherent differences between sonographic o/e-LHR
and MRI-derived rFLV measurement, which might explain why 3D-MRI measurement and thus
evaluation of rFLV may be the superior diagnostic tool to predict morbidity and mortality:
Ultrasound analysis only considers the lung contralateral to the diaphragm defect
whereas MRI evaluated rFLV includes the lung on the contralateral side and on the
ipsilateral side. This ipsilateral lung tissue if measured on a complementary basis
may allow for more precise prognosis concerning the need for ECMO and survival.
In line with previous results, our data confirm the predictive value of o/e-LHR and
rFLV in CDH with regard to the need for ECMO, the incidence of CLD, and survival to
discharge irrespective of the diagnostic modality. Concerning rFLV, there is also
a meta-analysis available confirming that higher observed-to-expected total fetal
lung volume is associated with higher chances of survival [17 ]. Health care providers should be aware of the fact that sonography can hardly discriminate
between the lowest o/e-LHR value groups and can even be unable to detect any o/e-LHR
below 15% at all as can be seen in our study. Despite this diagnostic uncertainty
in the lower o/e-LHR groups, it appeared that among the MRI-based modalities the Longest
Diameter method and the Tracing method are not superior to sonography and classification
of CDH according to o/e-LHR. Therefore, CDH severity could be easily assessed by every
clinician by measuring o/e-LHR in MRI data. All of the modalities tend to put many
fetuses in the best prognostic group based upon o/e-LHR evaluation. Hence for routine
assessment of CDH-affected fetuses, sonography is an adequate diagnostic tool and
remains the standard of care. However, sonography is an error-prone technique as it
depends perhaps more than any other technique on the experience and skills of the
examiner. Additionally, prenatal sonography can be difficult as visualization might
be compromised by the fetus’s position. These challenges can cause low measurement
reliability and reproducibility and justify efforts to standardize prenatal sonographic
examination for CDH [6 ]
[9 ]. Unsurprisingly, high reproducibility is a strength of MRI in the context of CDH
[8 ]
[10 ]
[18 ]. On the other hand, our data also indicate that the better a fetus is evaluated
based upon two-dimensional imaging (o/e-LHR >35%), the more likely this screening
method is inferior to a three-dimensional MRI evaluation of rFLV. It seems all the
other diagnostic methods tend to underestimate the morbidity of these fetuses as could
be concluded from the significant differences in the incidences of ECMO and CLD and
in the probability of survival to discharge with respect to the MRI Tracing method
compared to the rFLV in the clinically best fetuses (>35% o/e-LHR and rFLV, respectively).
Even though the prognostic accuracy for CDH morbidity and mortality based on ultrasound-evaluated
o/e-LHR increases if the position of the liver is taken into account [16 ], rFLV remains a promising prognostic tool.
Traditionally, o/e-LHR values above the cut-off of 35% are considered prognostically
favorable. In our cohort, the risk for ECMO among these fetuses still ranged between
36.2% and 42.2% and it was only reduced to 21.4% if rFLV also exceeded 35%. These
findings justify recommending fetal MRI to support or to challenge a relatively good
prognosis based upon sonography in order to plan conditions of delivery. However,
interestingly, even if the rFLV reached values of 35% and beyond, ECMO remained a
commonly used therapeutic intervention within our postnatal intensive care unit (21.4%).
This observation was also valid, if only liver-down neonates were considered. In this
subset, ECMO was used in 18.2% of cases. This may be due to severe pulmonary hypertension
that can also occur in patients with a good prognosis based on o/e-LHR. ECMO availability
and readiness may, therefore, be an important criterion when planning delivery of
CDH-affected children because, in our opinion, the rate of ECMO interventions in this
study may be the main reason for the high survival rates as suggested previously [19 ].
FETO holds an established position in the management of CDH ever since the TOTAL trial
attested a superior outcome in neonates with severe left-sided CDH treated with FETO
[20 ]. However, there is also evidence that survival might be even better if neonates
with severe LCDH receive ECMO instead of FETO [19 ]. Due to these promising data, in our very experienced ECMO center, FETO was reserved
for fetuses suffering from severe LCDH and exhibiting rFLV <25%.
Our prognostic abilities to predict morbidity and mortality of CDH-affected neonates
based on prenatal imaging involving sonography, prenatal MRI, and genetic testing
have developed immensely throughout recent years [21 ]
[22 ]. Interestingly, the lung-to-liver signal intensity ratio as evaluated by fetal MRI
was introduced as a novel prognostic tool to predict postnatal survival [23 ]. Today, rFLV values above 35% can predict survival in as much as 97% of all cases.
Yet, we do not know why the same cohort still suffers from chronic lung disease in
31.4% of cases or depends on ECMO in 21.4%. Therefore, we argue that it is necessary
to expand our view for future research and consider other prognostic parameters in
order to become more accurate in predicting morbidity. Especially prenatal predictability
of pulmonary hypertension could be a possible aim of future studies.
As one of the largest regional neonatal critical care centers, we are able to base
our studies on large case numbers. However, our analyses were restricted to MRI datasets
of inborn fetuses for methodologic reasons. Although MRI is considered the more reproducible
and objective diagnostic tool, our MRI dataset was also slightly incomplete due to
unfavorable positioning of the fetal head which prevented accurate measurements of
the head circumference. Results drawn from our study are limited due to the retrospective
design. Moreover, RCDH is a relatively rare condition compared to LCDH. Consequently,
the small number of RCDH cases did not allow for separate analysis of LCDH and RCDH.
Hence, we can only presume that our results are valid for both LCDH and RCDH.
Our data confirm the predictive value of o/e-LHR in fetuses with CDH irrespective
of the diagnostic method. MRI evaluation of o/e-LHR was not superior compared to sonographic
evaluation. Yet, MRI seemed to be beneficial with respect to the measurement of rFLV
particularly in fetuses who were otherwise classified with high o/e-LHR values as
two-dimensional evaluation methods tended to underestimate morbidity of the fetuses.
In our opinion, due to an unacceptable risk for ECMO, an external delivery cannot
be recommended even in such cases where prenatal diagnostic imaging would suggest
good prognosis based on rFLV >35% and absent liver herniation. Hence, we recommend
that every fetus with CDH requires a tertiary neonatal care unit with ECMO expertise
and readiness.